CNS Drugs

, Volume 21, Issue 10, pp 799–811 | Cite as

Hashimoto’s Encephalopathy

Epidemiology,Pathogenesis and Management
  • Ramon MocellinEmail author
  • Mark Walterfang
  • Dennis Velakoulis
Therapy In Practice


Hashimoto’s encephalopathy is a term used to describe an encephalopathy of presumed autoimmune origin characterised by high titres of antithyroid peroxidase antibodies. In a similar fashion to autoimmune thyroid disease, Hashimoto’s encephalopathy is more common in women than in men. It has been reported in paediatric, adult and elderly populations throughout the world. The clinical presentation may involve a relapsing and remitting course and include seizures, stroke-like episodes, cognitive decline, neuropsychiatric symptoms and myoclonus. Thyroid function is usually clinically and biochemically normal.

Hashimoto’s encephalopathy appears to be a rare disorder, but, as it is responsive to treatment with corticosteroids, it must be considered in cases of ‘investigation negative encephalopathies’. Diagnosis is made in the first instance by excluding other toxic, metabolic and infectious causes of encephalopathy with neuroimaging and CSF examination. Neuroimaging findings are often not helpful in clarifying the diagnosis. Common differential diagnoses when these conditions are excluded are Creutzfeldt-Jakob disease, rapidly progressive dementias, and paraneoplastic and nonparaneoplastic limbic encephalitis. In the context of the typical clinical picture, high titres of antithyroid antibodies, in particular antithyroid peroxidase antibodies, are diagnostic. These antibodies, however, can be detected in elevated titres in the healthy general population. Treatment with corticosteroids is almost always successful, although relapse may occur if this treatment is ceased abruptly. Other forms of immunomodulation, such as intravenous immune-globulin and plasma exchange, may also be effective.

Despite the link to autoimmune thyroid disease, the aetiology of Hashimoto’s encephalopathy is unknown. It is likely that antithyroid antibodies are not pathogenic, but titres can be a marker of treatment response. Pathological findings can suggest an inflammatory process, but features of a severe vasculitis are often absent. The links between the clinical pictures, thyroid disease, auto-antibody pattern and brain pathology await further clarification through research. It may be that Hashimoto’s encephalopathy will be subsumed into a group of nonvasculitic autoimmune inflammatory meningoencephalopathies. This group may include disorders such as limbic encephalitis associated with voltage-gated potassium channel antibodies. Some authors have suggested abandoning any link to Hashimoto and renaming the condition ‘steroid responsive encephalopathy associated with autoimmune thyroiditis’ to better reflect current, if limited, understanding of this condition.


Systemic Lupus Erythematosus Dementia With Lewy Body Autoimmune Thyroiditis Autoimmune Thyroid Disease Limbic Encephalitis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



No sources of funding were used to assist in the preparation of this review. The authors have no conflicts of interest that are directly relevant to the content of this review.


  1. 1.
    Brain L, Jellinek EH, Ball K. Hashimoto’s disease and encephalopathy. Lancet 1966 Sep 3; 2(7462): 512–4PubMedCrossRefGoogle Scholar
  2. 2.
    Ferracci F, Bertiato G, Moretto G. Hashimoto’s encephalopathy: epidemiologic data and pathogenetic considerations. J Neurol Sci 2004 Feb 15; 217(2): 165–8PubMedCrossRefGoogle Scholar
  3. 3.
    Chong JY, Rowland LP, Utiger RD. Hashimoto encephalopathy: syndrome or myth? Arch Neurol 2003 Feb; 60(2): 164–71PubMedCrossRefGoogle Scholar
  4. 4.
    Galluzzi S, Geroldi C, Zanetti O, et al. Hashimoto’s encephalopathy in the elderly: relationship to cognitive impairment. J Geriatr Psychiatry Neurol 2002; 15(3): 175–9PubMedGoogle Scholar
  5. 5.
    Vasconcellos E, Pina-Garza JE, Fakhoury T, et al. Pediatric manifestations of Hashimoto’s encephalopathy. Pediatr Neurol 1999 May; 20(5): 394–8PubMedCrossRefGoogle Scholar
  6. 6.
    Chaudhuri A, Behan PO. The clinical spectrum, diagnosis, pathogenesis and treatment of Hashimoto’s encephalopathy (recurrent acute disseminated encephalomyelitis). Curr Med Chem 2003 Oct; 10(19): 1945–53PubMedCrossRefGoogle Scholar
  7. 7.
    Byrne OC, Zuberi SM, Madigan CA, et al. Hashimoto’s thyroiditis: a rare but treatable cause of encephalopathy in children. Eur J Paediatr Neurol 2000; 4(6): 279–82PubMedCrossRefGoogle Scholar
  8. 8.
    Castillo P, Woodruff B, Caselli R, et al. Steroid-responsive encephalopathy associated with autoimmune thyroiditis. Arch Neurol 2006 Feb; 63(2): 197–202PubMedCrossRefGoogle Scholar
  9. 9.
    Tomer Y, Davies TF. Searching for the autoimmune thyroid disease susceptibility genes: from gene mapping to gene function. Endocr Rev 2003 Oct; 24(5): 694–717PubMedCrossRefGoogle Scholar
  10. 10.
    Ban Y, Tomer Y. Genetic susceptibility in thyroid autoimmunity. Pediatr Endocrinol Rev 2005 Sep; 3(1): 20–32PubMedGoogle Scholar
  11. 11.
    Fatourechi V. Hashimoto’s encephalopathy: myth or reality? An endocrinologist’s perspective. Best Pract Res Clin Endocrinol Metab 2005 Mar; 19(1): 53–66PubMedCrossRefGoogle Scholar
  12. 12.
    McCabe DJ, Burke T, Connolly S, et al. Amnesic syndrome with bilateral mesial temporal lobe involvement in Hashimoto’s encephalopathy. Neurology 2000; 54(3): 737–9PubMedCrossRefGoogle Scholar
  13. 13.
    Stone J, Campbell IW, Moran GD, et al. A case of reversible amnesia [letter]. Postgrad Med J 2001 Jan; 77(903): 56CrossRefGoogle Scholar
  14. 14.
    Ferlazzo E, Raffaele M, Mazzu I, et al. Recurrent status epilepticus as the main feature of Hashimoto’s encephalopathy. Epilepsy Behav 2006 Feb; 8(1): 328–30PubMedCrossRefGoogle Scholar
  15. 15.
    McGinley J, McCabe DJ, Fraser A, et al. Hashimoto’s encephalopathy: an unusual cause of status epilepticus [letter]. Ir ed J 2000 Jun; 93(4): 118Google Scholar
  16. 16.
    Arain A, Abou-Khalil B, Moses H. Hashimoto’s encephalopathy: documentation of mesial temporal seizure origin by ictal EEG. Seizure 2001 Sep; 10(6): 438–41PubMedGoogle Scholar
  17. 17.
    Sawka AM, Fatourechi V, Boeve BF, et al. Rarity of encephalopathy associated with autoimmune thyroiditis: a case series from Mayo Clinic from 1950 to 1996. Thyroid 2002; 12(5): 393–8PubMedCrossRefGoogle Scholar
  18. 18.
    Kothbauer-Margreiter I, Sturzenegger M, Komor J, et al. Encephalopathy associated with Hashimoto thyroiditis: diagnosis and treatment. J Neurol 1996 Aug; 243(8): 585–93PubMedCrossRefGoogle Scholar
  19. 19.
    Chaudhuri A, Behan PO. Hashimoto’s encephalopathy: a relapsing form of acute disseminated encephalomyelitis. J Neurol Sci 2005 Aug 15; 235(1–2): 75–6; author reply, 77PubMedCrossRefGoogle Scholar
  20. 20.
    Erickson JC, Carrasco H, Grimes JB, et al. Palatal tremor and myorhythmia in Hashimoto’s encephalopathy. Neurology 2002 Feb 12; 58(3): 504–5PubMedCrossRefGoogle Scholar
  21. 21.
    Taurin G, Golfier V, Pinel JF, et al. Choreic syndrome due to Hashimoto’s encephalopathy. Mov Disord 2002 Sep; 17(5): 1091–2PubMedCrossRefGoogle Scholar
  22. 22.
    Selim M, Drachman DA. Ataxia associated with Hashimoto’s disease: progressive non-familial adult onset cerebellar degeneration with autoimmune thyroiditis. J Neurol Neurosurg Psychiatry 2001 Jul; 71(1): 81–7PubMedCrossRefGoogle Scholar
  23. 23.
    Brusa L, Panella M, Koch G, et al. Hashimoto’s encephalopathy resenting with musical hallucinosis. J Neurol 2003 May; 250(5): 627–8PubMedCrossRefGoogle Scholar
  24. 24.
    Mahmud FH, Lteif AN, Renaud DL, et al. Steroid-responsive encephalopathy associated with Hashimoto’s thyroiditis in an adolescent with chronic hallucinations and depression: case report and review. Pediatrics 2003 Sep; 112(3 Pt 1): 686–90PubMedCrossRefGoogle Scholar
  25. 25.
    Mussig K, Bartels M, Gallwitz B, et al. Hashimoto’s encephalopathy presenting with bipolar affective disorder. Bipolar Disord 2005 Jun; 7(3): 292–7PubMedCrossRefGoogle Scholar
  26. 26.
    Papathanasopoulos P, Mallioris K, Karanasios P, et al. Febrile Hashimoto’s encephalopathy [letter]. J Neurol Neurosurg Psychiatry 2000 Jun; 68(6): 795PubMedCrossRefGoogle Scholar
  27. 27.
    Sellal F, Berton C, Andriantseheno M, et al. Hashimoto’s encephalopathy: exacerbations associated with menstrual cycle. Neurology 2002 Nov 26; 59(10): 1633–5PubMedCrossRefGoogle Scholar
  28. 28.
    Canton A, de Fabregas O, Tintore M, et al. Encephalopathy associated to autoimmune thyroid disease: a more appropriate term for an underestimated condition? J Neurol Sci 2000; 176(1): 65–9PubMedCrossRefGoogle Scholar
  29. 29.
    Chong JY, Rowland LP. What’s in a NAIM? Hashimoto encephalopathy, steroid-responsive encephalopathy associated with autoimmune thyroiditis, or nonvasculitic autoimmune meningoencephalitis? Arch Neurol 2006 Feb; 63(2): 175–6PubMedCrossRefGoogle Scholar
  30. 30.
    Oide T, Tokuda T, Yazaki M, et al. Anti-neuronal autoantibody in Hashimoto’s encephalopathy: neuropathological, immunohistochemical, and biochemical analysis of two patients. J Neurol Sci 2004 Jan 15; 217(1): 7–12PubMedCrossRefGoogle Scholar
  31. 31.
    Heufelder AE, Joba W, Morgenthaler NG. Autoimmunity involving the human sodium/iodide symporter: fact or fiction? Exp Clin Endocrinol Diabetes 2001; 109(1): 35–40PubMedCrossRefGoogle Scholar
  32. 32.
    Hollowell JG, Staehling NW, Flanders WD, et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 2002 Feb; 87(2): 489–99PubMedCrossRefGoogle Scholar
  33. 33.
    Fujii A, Yoneda M, Ito T, et al. Autoantibodies against the amino terminal of alpha-enolase are a useful diagnostic marker of Hashimoto’s encephalopathy. J Neuroimmunol 2005 May; 162(1–2): 130–6PubMedCrossRefGoogle Scholar
  34. 34.
    Ochi H, Horiuchi I, Araki N, et al. Proteomic analysis of human brain identifies alpha-enolase as a novel autoantigen in Hashimoto’s encephalopathy. FEBS Lett 2002 Sep 25; 528(1–3): 197–202PubMedCrossRefGoogle Scholar
  35. 35.
    Seipelt M, Zerr I, Nau R, et al. Hashimoto’s encephalitis as a differential diagnosis of Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry 1999; 66(2): 172–6PubMedCrossRefGoogle Scholar
  36. 36.
    Peschen-Rosin R, Schabet M, Dichgans J. Manifestation of Hashimoto’s encephalopathy years before onset of thyroid disease. Eur Neurol 1999; 41(2): 79–84PubMedCrossRefGoogle Scholar
  37. 37.
    Ferracci F, Moretto G, Candeago RM, et al. Antithyroid antibodies in the CSF: their role in the pathogenesis of Hashimoto’s encephalopathy. Neurology 2003 Feb 25; 60(4): 712–4PubMedCrossRefGoogle Scholar
  38. 38.
    Shiga Y, Wakabayashi H, Miyazawa K, et al. 14-3-3 protein levels and isoform patterns in the cerebrospinal fluid of Creutzfeldt-Jakob disease patients in the progressive and terminal stages. J Clin Neurosci 2006 Jul; 13(6): 661–5PubMedCrossRefGoogle Scholar
  39. 39.
    Vander T, Hallevy C, Alsaed I, et al. 14-3-3 protein in the CSF of a patient with Hashimoto’s encephalopathy. J Neurol 2004 Oct; 251(10): 1273–4PubMedCrossRefGoogle Scholar
  40. 40.
    Schauble B, Castillo PR, Boeve BF, et al. EEG findings in steroid-responsive encephalopathy associated with autoimmune thyroiditis. Clin Neurophysiol 2003 Jan; 114(1): 32–7PubMedCrossRefGoogle Scholar
  41. 41.
    Song YM, Seo DW, Chang GY. MR findings in Hashimoto encephalopathy. AJNR Am J Neuroradiol 2004 May; 25(5): 07–8Google Scholar
  42. 42.
    Bohnen NI, Parnell KJ, Harper CM. Reversible MRI findings in a patient with Hashimoto’s encephalopathy. Neurology 1997; 49(1): 246–7PubMedCrossRefGoogle Scholar
  43. 43.
    Pozo-Rosich P, Villoslada P, Canton A, et al. Reversible white matter alterations in encephalopathy associated with autoimmune thyroid disease. J Neurol 2002 Aug; 249(8): 1063–5PubMedCrossRefGoogle Scholar
  44. 44.
    Bertoni M, Falcini M, Sestini S, et al. Encephalopathy associated with Hashimoto’s thyroiditis: an additional case. Eur J Intern Med 2003 Nov; 14(7): 434–7PubMedCrossRefGoogle Scholar
  45. 45.
    Forchetti CM, Katsamakis G, Garron DC. Autoimmune thyroiditis and a rapidly progressive dementia: global hypoperfusion on SPECT scanning suggests a possible mechanism. Neurology 1997 Aug; 49(2): 623–6PubMedCrossRefGoogle Scholar
  46. 46.
    Josephson SA, Papanastassiou AM, Berger MS, et al. The diagnostic utility of brain biopsy procedures in patients with rapidly deteriorating neurological conditions or dementia. J Neurosurg 2007 Jan; 106(1): 72–5PubMedCrossRefGoogle Scholar
  47. 47.
    Warren JD, Schott JM, Fox NC, et al. Brain biopsy in dementia. Brain 2005 Sep; 128(Pt 9): 2016–25PubMedCrossRefGoogle Scholar
  48. 48.
    Jennekens FG, Kater L. The central nervous system in systemic upus erythematosus (Pt 1). Clinical syndromes: a literature investigation. Rheumatology (Oxford) 2002 Jun; 41(6): 605–18Google Scholar
  49. 49.
    Bruns A, Meyer O. Neuropsychiatric manifestations of systemic lupus erythematosus. Joint Bone Spine 2006 Dec; 73(6): 639–45PubMedCrossRefGoogle Scholar
  50. 50.
    Jennekens FG, Kater L. The central nervous system in systemic lupus erythematosus (Pt 2). Pathogenetic mechanisms of clinical syndromes: a literature investigation. Rheumatology (Oxford) 2002 Jun; 41(6): 619–30Google Scholar
  51. 51.
    Sanna G, Bertolaccini ML, Mathieu A. Central nervous system lupus: a clinical approach to therapy. Lupus 2003; 12(12): 935–42PubMedCrossRefGoogle Scholar
  52. 52.
    Sanna G, Bertolaccini ML, Cuadrado MJ, et al. Neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies. J Rheumatol 2003 May; 30(5): 985–92PubMedGoogle Scholar
  53. 53.
    Johnson RT, Gibbs Jr CJ. Creutzfeldt-Jakob disease and related transmissible spongiform encephalopathies. N Engl J Med 1998 Dec 31; 339(27): 1994–2004PubMedCrossRefGoogle Scholar
  54. 54.
    Calabrese L. Primary angiitis of the central nervous system: the penumbra of vasculitis. J Rheumatol 2001; 28(3): 465–6PubMedGoogle Scholar
  55. 55.
    Imbesi SG. Diffuse cerebral vasculitis with normal results on brain MR imaging. AJR Am J Roentgenol 1999; 173(6): 1494–6PubMedGoogle Scholar
  56. 56.
    Wasserman BA, Stone JH, Hellmann DB, et al. Reliability of normal findings on MR imaging for excluding the diagnosis of vasculitis of the central nervous system. AJR Am J Roentgenol 2001; 177(2): 455–9PubMedGoogle Scholar
  57. 57.
    Alrawi A, Trobe JD, Blaivas M, et al. Brain biopsy in primary angiitis of the central nervous system. Neurology 1999 Sep 11; 53(4): 858–60PubMedCrossRefGoogle Scholar
  58. 58.
    Caturegli P, Newschaffer C, Olivi A, et al. Autoimmune hypophysitis. Endocr Rev 2005 Aug; 26(5): 599–614PubMedCrossRefGoogle Scholar
  59. 59.
    Miyake I, Takeuchi Y, Kuramoto T, et al. Autoimmune hypophysitis treated with intravenous glucocorticoid therapy. Intern Med 2006; 45(21): 1249–52PubMedCrossRefGoogle Scholar
  60. 60.
    Rivera JA. Lymphocytic hypophysitis: disease spectrum and approach to diagnosis and therapy. Pituitary 2006; 9(1): 35–45PubMedCrossRefGoogle Scholar
  61. 61.
    Mocellin R, Velakoulis D, Gonzales M, et al. Weight loss, falls, and neuropsychiatric symptoms in a 56 year-old man. Lancet Neurol 2005 Jun; 4(6): 381–8PubMedCrossRefGoogle Scholar
  62. 62.
    Vincent A, Buckley C, Schott JM, et al. Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis. Brain 2004 Mar; 127(Pt 3): 701–12PubMedGoogle Scholar
  63. 63.
    Thieben MJ, Lennon VA, Boeve BF, et al. Potentially reversible autoimmune limbic encephalitis with neuronal potassium channel antibody. Neurology 2004 Apr 13; 62(7): 1177–82PubMedCrossRefGoogle Scholar
  64. 64.
    Urbach H, Soeder BM, Jeub M, et al. Serial MRI of limbic encephalitis. Neuroradiology 2006 Jun; 48(6): 380–6PubMedCrossRefGoogle Scholar
  65. 65.
    Sener R. MRI and diffusion MRI in nonparaneoplastic limbic encephalitis. Comput Med Imaging Graph 2002; 26(5): 339–42PubMedCrossRefGoogle Scholar
  66. 66.
    Fauser S, Talazko J, Wagner K, et al. FDG-PET and MRI in potassium channel antibody-associated non-paraneoplastic limbic encephalitis: correlation with clinical course and neuropsychology. Acta Neurol Scand 2005 May; 111(5): 338–43PubMedCrossRefGoogle Scholar
  67. 67.
    Caviness JN. Myoclonus and neurodegenerative disease: what’s in a name? Parkinsonism Relat Disord 2003 Mar; 9(4): 185–92PubMedCrossRefGoogle Scholar
  68. 68.
    McKeith IG, Burn DJ, Ballard CG, et al. Dementia with Lewy bodies. Semin Clin Neuropsychiatry 2003; 8(1): 46–57PubMedCrossRefGoogle Scholar
  69. 69.
    Walker Z, Stevens T. Dementia with Lewy bodies: clinical characteristics and diagnostic criteria. J Geriatr Psychiatry Neurol 2002; 15(4): 188–94PubMedGoogle Scholar
  70. 70.
    Caviness JN, Adler CH, Caselli RJ, et al. Electrophysiology of the myoclonus in dementia with Lewy bodies. Neurology 2003 Feb 11; 60(3): 523–4PubMedCrossRefGoogle Scholar
  71. 71.
    Tschampa HJ, Neumann M, Zerr I, et al. Patients with Alzheimer’s disease and dementia with Lewy bodies mistaken for Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry 2001; 71(1): 33–9PubMedCrossRefGoogle Scholar
  72. 72.
    Dickson DW, Bergeron C, Chin SS, et al. Office of Rare Diseases neuropathologic criteria for corticobasal degeneration. J Neuropathol Exp Neurol 2002; 61(11): 935–46PubMedGoogle Scholar
  73. 73.
    Coulier IM, de Vries JJ, Leenders KL. Is FDG-PET a useful tool in clinical practice for diagnosing corticobasal ganglionic degeneration? Mov Disord 2003 Oct; 18(10): 1175–8PubMedCrossRefGoogle Scholar
  74. 74.
    Velakoulis D, Lloyd JH. The role of SPECT scanning in a neuropsychiatry unit. Aust N Z J Psychiatry 1998 Aug; 32(4): 511–22PubMedCrossRefGoogle Scholar
  75. 75.
    Graham NL, Bak TH, Hodges JR. Corticobasal degeneration as a cognitive disorder. Mov Disord 2003 Nov; 18(11): 1224–32PubMedCrossRefGoogle Scholar
  76. 76.
    Shovman O, Gilburd B, Zandman-Goddard G, et al. Pathogenic role and clinical relevance of antineutrophil cytoplasmic antibodies in vasculitides. Curr Rheumatol Rep 2006 Aug; 8(4): 292–8PubMedCrossRefGoogle Scholar
  77. 77.
    Paulus W, Nolte KW. Neuropathology of Hashimoto’s encephalopathy. J Neurol Neurosurg Psychiatry 2003 Jul; 74(7):1009; author reply, 1009PubMedCrossRefGoogle Scholar
  78. 78.
    Duffey P, Yee S, Reid IN, et al. Hashimoto’s encephalopathy: postmortem findings after fatal status epilepticus. Neurology 2003 Oct 28; 61(8): 1124–6PubMedCrossRefGoogle Scholar
  79. 79.
    Josephs KA, Rubino FA, Dickson DW. Nonvasculitic autoimmune inflammatory meningoencephalitis. Neuropathology 2004 Jun; 24(2): 149–52PubMedCrossRefGoogle Scholar
  80. 80.
    Mahad DJ, Staugaitis S, Ruggieri P, et al. Steroid-responsive encephalopathy associated with autoimmune thyroiditis and primary CNS demyelination. J Neurol Sci 2005 Jan 15; 228(1): 3–5PubMedCrossRefGoogle Scholar
  81. 81.
    Mikaeloff Y, Caridade G, Husson B, et al. Acute disseminated encephalomyelitis cohort study: prognostic factors for relapse. Eur J Paediatr Neurol 2007; 11(2): 90–5PubMedCrossRefGoogle Scholar
  82. 82.
    Rodien P, Madec AM, Ruf J, et al. Antibody-dependent cell-mediated cytotoxicity in autoimmune thyroid disease: relationship to antithyroperoxidase antibodies. J Clin Endocrinol Metab 1996 Jul; 81(7): 2595–600PubMedCrossRefGoogle Scholar
  83. 83.
    Jacob S, Rajabally YA. Hashimoto’s encephalopathy: steroid resistance and response to intravenous immunoglobulins. J Neurol Neurosurg Psychiatry 2005 Mar; 76(3): 455–6PubMedCrossRefGoogle Scholar
  84. 84.
    Sambrook PN. How to prevent steroid induced osteoporosis. Ann Rheum Dis 2005 Feb; 64(2): 176–8PubMedCrossRefGoogle Scholar
  85. 85.
    Badsha H, Edwards CJ. Intravenous pulses of methylprednisolone for systemic lupus erythematosus. Semin Arthritis Rheum 2003 Jun; 32(6): 370–7PubMedCrossRefGoogle Scholar
  86. 86.
    Marshall GA, Doyle JJ. Long-term treatment of Hashimoto’s encephalopathy. J Neuropsychiatry Clin Neurosci 2006; 18(1): 14–20PubMedCrossRefGoogle Scholar
  87. 87.
    Shaw PJ, Walls TJ, Newman PK, et al. Hashimoto’s encephalopathy: a steroid-responsive disorder associated with high anti-thyroid antibody titers: report of 5 cases. Neurology 1991; 41(2 Pt 1): 228–33PubMedCrossRefGoogle Scholar
  88. 88.
    Nagpal T, Pande S. Hashimoto’s encephalopathy: response to plasma exchange. Neurol India 2004 Jun; 52(2): 245–7PubMedGoogle Scholar
  89. 89.
    Boers PM, Colebatch JG. Hashimoto’s encephalopathy responding to plasmapheresis [letter]. J Neurol Neurosurg Psychiatry 2001; 70(1): 132PubMedCrossRefGoogle Scholar
  90. 90.
    Fatemi S, Bedri J, Nicoloff JT. Encephalopathy associated with Hashimoto’s thyroiditis: use of serum immunoglobulin G as a marker of disease activity. Thyroid 2003 Feb; 13(2): 227–8PubMedCrossRefGoogle Scholar
  91. 91.
    Caselli RJ, Boeve BF, Scheithauer BW, et al. Nonvasculitic autoimmune inflammatory meningoencephalitis (NAIM): a reversible form of encephalopathy. Neurology 1999 Oct 22; 53(7): 1579–81PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2007

Authors and Affiliations

  • Ramon Mocellin
    • 1
    • 2
    Email author
  • Mark Walterfang
    • 1
    • 2
  • Dennis Velakoulis
    • 1
    • 2
  1. 1.Neuropsychiatry UnitThe Royal Melbourne HospitalParkvilleAustralia
  2. 2.Melbourne Neuropsychiatry Centre, Department of PsychiatryUniversity of MelbourneParkvilleAustralia

Personalised recommendations